Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 5/20 | 0.44 |
| ▸ | FAP | Q12884 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL268273 | 1.00 | KMT2A (0.48) | KMT2AALDH1A1CYP3A4CYP2C19DPP4 | |
| SCHEMBL268274 | 1.00 | KMT2A (0.48) | KMT2AALDH1A1CYP3A4CYP2C19DPP4 | |
| Hydrochloric Acid SCHEMBL1068706 | 0.98 | KMT2A (0.47) | KMT2AALDH1A1CYP3A4CYP2C19DPP4 | |
| Hydrochloric Acid SCHEMBL30831586 | 0.98 | KMT2A (0.47) | KMT2AALDH1A1CYP3A4CYP2C19DPP4 | |
| Hydrochloric Acid SCHEMBL5561971 | 0.98 | KMT2A (0.47) | KMT2AALDH1A1CYP3A4CYP2C19DPP4 | |
| Hydrochloric Acid SCHEMBL5561964 | 0.98 | KMT2A (0.47) | KMT2AALDH1A1CYP3A4CYP2C19DPP4 | |
| SCHEMBL7244017 | 0.94 | ALDH1A1 (0.47) | KMT2AALDH1A1CYP3A4CYP2C19DPP4 | |
| SCHEMBL7342562 | 0.86 | ALDH1A1 (0.48) | KMT2AALDH1A1DPP4FAPDPP8 | |
| SCHEMBL20543771 | 0.86 | ALDH1A1 (0.48) | KMT2AALDH1A1DPP4FAPDPP8 | |
| SCHEMBL21117726 | 0.86 | ALDH1A1 (0.48) | KMT2AALDH1A1DPP4FAPDPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012120532-A2 | CYCLIC SHORT CHAIN PEPTIDES | CADILA HEALTHCARE LIMITED (IN) | 2012-09-13 | — | — | WO | claimed |
| EP-2421893-A2 | SHORT-CHAIN PEPTIDES AS PARATHYROID HORMONE (PTH) RECEPTOR AGONIST | Cadila Healthcare Limited (IN) | 2012-02-29 | — | — | EP | claimed |
| WO-2010128521-A2 | SHORT-CHAIN PEPTIDES AS PARATHYROID HORMONE (PTH) RECEPTOR AGONIST | CADILA HEALTHCARE LIMITED (IN) | 2010-11-11 | — | — | WO | claimed |
| EP-3303367-B1 | STABILIZED MINIMAL COILED-COIL MIMETICS | UNIV NEW YORK (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-115572326-B | Triple agonists of GLP-1, GCG and GIP receptors | 广东东阳光药业股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-114787183-B | Incretin analogues and uses thereof | 伊莱利利公司 | 2024-11-26 | — | — | CN | disclosed |
| US-20240124539-A1 | CROSSLINKED HELIX DIMER MIMICS OF SOS AND METHODS OF USING SAME | NEW YORK UNIVERSITY | 2024-04-18 | — | — | US | disclosed |
| EP-4312982-A1 | INCRETIN ANALOG-CONTAINING COMPOSITIONS AND USES THEREOF | Eli Lilly and Company (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20240034753-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2024-02-01 | — | — | US | disclosed |
| CN-117417411-A | GLP-1/GCG/GIP tri-receptor agonists and uses thereof | 广东东阳光药业股份有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-117042754-A | Composition containing incretin analogue and application thereof | 伊莱利利公司 | 2023-11-10 | — | — | CN | disclosed |
| US-7741327-B2 | Pyrrolidinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| WO-2009127546-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | WO | disclosed |
| EP-2084182-A2 | ANTIDIABETIC COMPOUNDS | Cadila Healthcare Limited (IN) | 2009-08-05 | — | — | EP | disclosed |
| EP-2021014-A1 | SUSTAINED RELEASE GLP-1 RECEPTOR MODULATORS | Brystol-Myers Squibb Company (US) | 2009-02-11 | — | — | EP | disclosed |
| WO-2008062457-A2 | ANTIDIABETIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2008-05-29 | — | — | WO | disclosed |
| EP-1883652-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2008-02-06 | — | — | EP | disclosed |
| WO-2007139589-A1 | SUSTAINED RELEASE GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2006127948-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | GCKR, GCK, PDK2 | KMT2A 2072/4885ALDH1A1 1129/4885CYP3A4 2098/4885 |
| US-20240124539-A1 | CROSSLINKED HELIX DIMER MIMICS OF SOS AND METHODS OF USING SAME | SOS2, SOS1, F2 | KMT2A 4401/4885ALDH1A1 3199/4885CYP3A4 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.